Cytokine Signalling Forum

Publications





May 18

Pharmacocinétique de l’Upadacitinib avec des schémas cliniques de la formulation à libération prolongée utilisée dans les essais de phase 3 sur la polyarthrite rhumatoïde

Mohamed MEF, Zeng J, Marroum PJ, Song IH, Othman AA.
Clin Pharmacol Drug Dev. 2019 Feb;8(2):208-216. doi: 10.1002/cpdd.462

Upadacitinib (UPA) extended release (ER) formulation dosing achieved the target profile that enables single dosing in patients with RA. In early clinical studies, UPA was given as an immediate release (IR) formulation, however patients were noted to experience fluctuations in blood plasma concentrations. To enhance patient compliance in UPA Phase 3 trials, ER tablets have been developed. Here, authors aimed at characterising the pharmacokinetics of UPA single and multiple doses of ER compared ...

Mots clefs: JAK, Upadacitinib, Preclinical, PK-PD

Traduit par: Helena Farese